Trial Profile
Safety and efficacy of pembrolizumab as first-line treatment in non-small cell lung cancer patients with poor performance status: a pilot study.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 May 2019
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 05 May 2019 Status changed from recruiting to discontinued.
- 22 Oct 2017 New trial record